阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3214人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2048011, encodeId=02c6204801186, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, objectType=article, longId=162148, objectId=423a1621482c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423a1621482c, replyNumber=0, likeNumber=80, createdTime=2019-03-18, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423a1621482c, moduleTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423a1621482c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048016, encodeId=a9a62048016ed, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌, objectType=article, longId=164505, objectId=a10e164505e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a10e164505e1, replyNumber=0, likeNumber=61, createdTime=2019-11-08, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a10e164505e1, moduleTitle=Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a10e164505e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047987, encodeId=06e0204e987da, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌只能化疗？这些治疗手段指日可待, objectType=article, longId=146920, objectId=89d6146920d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89d6146920d5, replyNumber=0, likeNumber=72, createdTime=2018-11-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89d6146920d5, moduleTitle=三阴性乳腺癌只能化疗？这些治疗手段指日可待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89d6146920d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047985, encodeId=ab69204e985a0, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Signal Transduct Target Ther：靶向MUC1-C可抑制三阴性乳腺癌中的BCL2A1, objectType=article, longId=138429, objectId=e601138429e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e601138429e0, replyNumber=0, likeNumber=62, createdTime=2019-01-13, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e601138429e0, moduleTitle=Signal Transduct Target Ther：靶向MUC1-C可抑制三阴性乳腺癌中的BCL2A1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e601138429e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047991, encodeId=0bf3204e99194, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Cell：重磅！三阴性乳腺癌根源现世！这个基因是罪魁祸首！, objectType=article, longId=148180, objectId=4e7f148180c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7f148180c3, replyNumber=0, likeNumber=129, createdTime=2018-12-18, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7f148180c3, moduleTitle=Cancer Cell：重磅！三阴性乳腺癌根源现世！这个基因是罪魁祸首！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7f148180c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048014, encodeId=f7a820480144c, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, objectType=article, longId=163455, objectId=500616345538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500616345538, replyNumber=0, likeNumber=49, createdTime=2019-07-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500616345538, moduleTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500616345538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047983, encodeId=e388204e98325, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, objectType=article, longId=137196, objectId=7db713e1967a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db713e1967a, replyNumber=0, likeNumber=64, createdTime=2019-04-13, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db713e1967a, moduleTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7db713e1967a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048008, encodeId=259b204800887, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, objectType=article, longId=160705, objectId=9197160e05e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9197160e05e2, replyNumber=0, likeNumber=87, createdTime=2019-12-31, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9197160e05e2, moduleTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9197160e05e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047995, encodeId=cfb4204e99536, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=PNAS：重磅！攻破三阴性乳腺癌！梅奥诊所发现新药物疗法！, objectType=article, longId=150832, objectId=378115083246, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=378115083246, replyNumber=0, likeNumber=63, createdTime=2018-10-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=378115083246, moduleTitle=PNAS：重磅！攻破三阴性乳腺癌！梅奥诊所发现新药物疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=378115083246)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047988, encodeId=86a7204e9887f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, objectType=article, longId=147408, objectId=1ea914e40885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ea914e40885, replyNumber=0, likeNumber=63, createdTime=2019-07-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ea914e40885, moduleTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ea914e40885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048009, encodeId=729820480093c, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=“智能药物”显示出转移性三阴性乳腺癌的治疗前景, objectType=article, longId=161063, objectId=ec89161063e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec89161063e5, replyNumber=0, likeNumber=67, createdTime=2019-03-29, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec89161063e5, moduleTitle=“智能药物”显示出转移性三阴性乳腺癌的治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec89161063e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047977, encodeId=5886204e977c4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, objectType=article, longId=131089, objectId=56eb131089ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56eb131089ae, replyNumber=0, likeNumber=53, createdTime=2018-12-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56eb131089ae, moduleTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56eb131089ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048005, encodeId=6021204800551, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后, objectType=article, longId=155771, objectId=2def155e7198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2def155e7198, replyNumber=0, likeNumber=0, createdTime=2019-05-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2def155e7198, moduleTitle=CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2def155e7198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047989, encodeId=4041204e989ae, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=NAT COMMUN:中科院詹丽杏研究组发现三阴性乳腺癌治疗新靶标, objectType=article, longId=147851, objectId=ca1714e8511b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca1714e8511b, replyNumber=0, likeNumber=81, createdTime=2018-09-06, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca1714e8511b, moduleTitle=NAT COMMUN:中科院詹丽杏研究组发现三阴性乳腺癌治疗新靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca1714e8511b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047994, encodeId=6002204e994bd, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JCO：紫杉醇联合LCL161治疗三阴性乳腺癌, objectType=article, longId=149301, objectId=e301149301c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e301149301c0, replyNumber=0, likeNumber=53, createdTime=2019-05-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e301149301c0, moduleTitle=JCO：紫杉醇联合LCL161治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e301149301c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047974, encodeId=b577204e9749a, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ANN ONCOL：三阴性乳腺癌基因特征预测患者结局, objectType=article, longId=127484, objectId=5e6012e48489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e6012e48489, replyNumber=0, likeNumber=87, createdTime=2018-12-26, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e6012e48489, moduleTitle=ANN ONCOL：三阴性乳腺癌基因特征预测患者结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6012e48489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047972, encodeId=f6d6204e972e2, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Discov：基于小鼠模型鉴定三阴性乳腺癌散发型致癌基因突变及治疗策略, objectType=article, longId=125796, objectId=002a125e96ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=002a125e96ba, replyNumber=0, likeNumber=111, createdTime=2018-03-14, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=002a125e96ba, moduleTitle=Cancer Discov：基于小鼠模型鉴定三阴性乳腺癌散发型致癌基因突变及治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=002a125e96ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047986, encodeId=7c01204e98629, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JNCI；建议对三阴性乳腺癌进行多基因遗传肿瘤panel检测, objectType=article, longId=146519, objectId=6fa5146519a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fa5146519a0, replyNumber=0, likeNumber=88, createdTime=2019-05-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fa5146519a0, moduleTitle=JNCI；建议对三阴性乳腺癌进行多基因遗传肿瘤panel检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fa5146519a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047970, encodeId=5b5d204e9707f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, objectType=article, longId=120634, objectId=1dba1206345c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dba1206345c, replyNumber=0, likeNumber=61, createdTime=2018-03-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dba1206345c, moduleTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dba1206345c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047982, encodeId=add5204e98285, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=袁芃教授：晚期三阴性乳腺癌内科治疗进展（一）, objectType=article, longId=136750, objectId=dacf136e50e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dacf136e50e9, replyNumber=0, likeNumber=81, createdTime=2018-10-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dacf136e50e9, moduleTitle=袁芃教授：晚期三阴性乳腺癌内科治疗进展（一）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dacf136e50e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准

2019-03-18

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌

2019-11-08

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌只能化疗？这些治疗手段指日可待

2018-11-04

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Signal Transduct Target Ther：靶向MUC1-C可抑制三阴性乳腺癌中的BCL2A1

2019-01-13

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Cell：重磅！三阴性乳腺癌根源现世！这个基因是罪魁祸首！

2018-12-18

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％

2019-07-24

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究

2019-04-13

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌

2019-12-31

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

PNAS：重磅！攻破三阴性乳腺癌！梅奥诊所发现新药物疗法！

2018-10-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌

2019-07-24

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

“智能药物”显示出转移性三阴性乳腺癌的治疗前景

2019-03-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响

2018-12-25

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后

2019-05-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

NAT COMMUN:中科院詹丽杏研究组发现三阴性乳腺癌治疗新靶标

2018-09-06

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JCO：紫杉醇联合LCL161治疗三阴性乳腺癌

2019-05-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ANN ONCOL：三阴性乳腺癌基因特征预测患者结局

2018-12-26

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Discov：基于小鼠模型鉴定三阴性乳腺癌散发型致癌基因突变及治疗策略

2018-03-14

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JNCI；建议对三阴性乳腺癌进行多基因遗传肿瘤panel检测

2019-05-24

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌

2018-03-25

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

袁芃教授：晚期三阴性乳腺癌内科治疗进展（一）

2018-10-25

科室
- - 订阅+
  - 更多科室
工具
服务